Prediction of chronic renal insufficiency after coronary angiography by an early increase in oxidative stress and decrease in glomerular filtration rate

Circulation Journal

Volumn 75, Issue 2, 2011, Pages 437-442

  Tajiri, Kazuko ^a   Maruyama, Hidekazu ^a   Sato, Akira ^a   Shimojo, Nobutake ^a   Saito, Takumi ^b   Endo, Masae ^b   Aihara, Hideaki ^b   Kawano, Satoru ^a   Watanabe, Shigeyuki ^a   Sakai, Satoshi ^a   Aonuma, Kazutaka ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Department of Neurosurgery   (Japan)

Author keywords

Contrast medium; Contrast induced nephropathy; Coronary angiography; Oxidative stress

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IOMEPROL; IOMERON 350; ISOPROSTANE DERIVATIVE; LOOP DIURETIC AGENT; UNCLASSIFIED DRUG;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MALE; OXIDATIVE STRESS; PREDICTION; PROSPECTIVE STUDY; PROSTAGLANDIN URINE LEVEL; RISK FACTOR;

ACETYLGLUCOSAMINIDASE; ACUTE KIDNEY INJURY; AGED; BIOLOGICAL MARKERS; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; DIABETES MELLITUS; DYSLIPIDEMIAS; F2-ISOPROSTANES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; IOPAMIDOL; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 79251578026     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0622     Document Type: Article

References (32)

1. Abe M, Kimura T, Morimoto T, Furukawa Y, Kita T. Incidence of and risk factors for contrast-induced nephropathy after cardiac catheterization in Japanese patients. Circ J 2009; 73: 1518-1522.
2. Briguori C, Tavano D, Colombo A. Contrast agent--associated nephrotoxicity. Prog Cardiovasc Dis 2003; 45: 493-503.
3. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-375.
4. Baker CS, Baker LR. Prevention of contrast nephropathy after cardiac catheterization. Heart 2001; 85: 361-362.
5. Pitsavos C, Kourlaba G, Panagiotakos DB, Kogias Y, Mantas Y, Chrysohoou C, et al. Association of creatinine clearance and inhospital mortality in patients with acute coronary syndrome: The GREECS study. Circ J 2007; 71: 9-14.
6. Morcos SK. Contrast media-induced nephrotoxicity--questions and answers. Br J Radiol 1998; 71: 357-365.
7. Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol 2003; 76: 513-518.
8. Katzberg RW. Contrast medium-induced nephrotoxicity: Which pathway? Radiology 2005; 235: 752-755.
9. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado César LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: Decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 2004; 19: 1803-1807.
10. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184.
11. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylsysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89: 356-358.
12. Kay J. Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, et al. Acetylsysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: A randomized controlled trial. JAMA 2003; 289: 553-558.
13. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 41-50.
14. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28: 505-513.
15. Shiragami K, Fujii Z, Sakumura T, Shibuya M, Takahashi N, Yano M, et al. Effect of a contrast agent on long-term renal function and the efficacy of prophylactic hemodiafiltration. Circ J 2008; 72: 427-433.
16. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital- acquired renal insufficiency: A prospective study. Am J Med 1983; 74: 243-248.
17. Duarte CG, Zhang J, Ellis S. The SHR as a small animal model for radiocontrast renal failure. Relation of nephrotoxicity to animal's age, gender, strain, and dose of radiocontrast. Ren Fail 1997; 19: 723-743.
18. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36: 1542-1548.
19. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: A prospective cohort study. J Am Soc Nephrol 2004; 15: 1597-1605.
20. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: Pathogenesis, risk factors and preventive strategies. CMAJ 2005; 172: 1461-1471.
21. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416-1420.
22. Iwanaga, Y, Miyazaki S. Heart failure, chronic kidney disease, and biomarkers: An integrated viewpoint. Circ J 2010; 74: 1274-1282.
23. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 1997; 29: 465-477.
24. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr. Radiocontrast medium-induced declines in renal function: A role for oxygen free radicals. Am J Physiol 1990; 258: F115-F120.
25. Barrett BJ. Contrast nephrotoxicity. J Am Soc Nephrol 1994; 5: 125-137.
26. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R. N-acetyl cysteine ameliorates ischemic renal failure. Am J Physiol 1997; 272: F292-F298.
27. Salom MG, Ramírez P, Carbonell LF, López Conesa E, Cartagena J, Quesada T, et al. Protective effect of N-acetyl-L-cysteine on the renal failure induced by inferior vena cava occlusion. Transplantation 1998; 65: 1315-1321.
28. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado César LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: Decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 2004; 19: 1803-1807.
29. Lapenna D, De Gioia S, Mezzetti A, Ciofani G, Festi D, Cuccurullo F. Aminophylline: Could it act as an antioxidant in vivo? Eur J Clin Invest 1995; 25: 464-470.
30. Huber W, Ilgmann K, Page M, Hennig M, Schweigart U, Jeschke B, et al. Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: Controlled, randomized, double-blinded study. Radiology 2002; 223: 772-779.
31. Huber W, Eckel F, Hennig M, Rosenbrock H, Wacker A, Saur D, et al. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: Acethylcysteine, theophyline, or both? A randomized study. Radiology 2006; 239: 793-804.
32. Masuda M, Yamada T, Okuyama Y, Morita T, Sanada S, Furukawa Y, et al. Sodium bicarbonate improves long-term clinical outcomes compared with sodium chloride in patients with chronic kidney disease undergoing an emergent coronary procedure. Circ J 2008; 72: 1610-1614.